UPDATE: Raymond James Starts Agios Pharma (AGIO) at Market Perform

Raymond James analyst Danielle Brill initiates coverage on Agios Pharma (NASDAQ: AGIO) with a Market Perform rating.

The analyst comments "We are initiating coverage of Agios with a Market Perform rating. We expect the stock to remain strong for the duration of the share repurchase program, but believe the value that is expected to be returned to shareholders is already reflected in share price, as is the majority of mitapivat's commercial opportunity in lead indications (PKD (pyruvate kinase deficiency), and thal). Furthermore, Agios has indicated the majority of the share buybacks will be completed by YE21, and moving forward over the course of 2022, we anticipate stock volatility related to 1) Regulatory risk and likely Advisory Committee panel for mitapivat and 2) a potentially slow commercial launch in PKD (especially considering the majority of prevalent population has not yet been clearly identified)."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $53.53 yesterday.

You May Also Be Interested In

• Scotiabank Starts Webull (BULL) at Sector Outperform
• Scotiabank Starts SoFi Technologies (SOFI) at Sector Outperform
• Cantor Fitzgerald Starts Tempus AI Inc (TEM) at Overweight